On May 01, 2014, Merrimack Pharmaceuticals Inc (NASDAQ:MACK), announced that its Phase 3 study of the combination of MM-398 with 5-fluorouracil and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), shares after opening at $7.45 moved to $7.65 on last trade day and at the end of the day closed at $6.95. Company price to sales ratio in past twelve months was calculated as 15.10 and price to cash ratio as 4.65. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), showed a positive weekly performance of 44.72%.
Gilead Sciences, Inc. (NASDAQ:GILD), jumped 0.68% with high volume of 15.97 million shares. Recently Gregg Alton, executive vice president for Gilead’s corporate and medical affairs, told an audience at the Milken Institute’s Global Conference in Beverly Hills, Calif., that the $84,000 price tag for Sovaldi is proving to be cheaper and more effective than past treatments for hepatitis C. Gilead Sciences, Inc. (NASDAQ:GILD), shares advanced 0.68% in last trading session and ended the day on $79.02. Gilead Sciences, Inc. (NASDAQ:GILD), return on equity ratio is recorded as 38.90% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD), yearly performance is 57.60%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s shares fell 6.75% to $0.89. The company on Apr. 21 announced promising preclinical results for RX-21101, the Company’s first development candidate derived from its Nano-Polymer-Drug Conjugate System (NPDCS) platform. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), shares moved down 6.25% in last trading session and was closed at $0.890, while trading in range of $ 0.83 – 0.95. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), year to date (YTD) performance is 74.51%.
Ariad Pharmaceuticals (NASDAQ:ARIA) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 42,213,990 shares, a growth of 6.4% from the March 31st total of 39,661,474 shares, AR Network reports. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), weekly performance is 0.40%. On last trading day company shares ended up $7.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), distance from 50-day simple moving average (SMA50) is -4.93%. Analysts mean target Price for the company is $9.06.